Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes
Key facts
- Who runs it
- Lin Chen
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 150 people enrolled
- Started
- 1 Jan 2021
- Ended
- 31 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- esmolol
- Record updated
- 29 May 2024
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- Patients aged between 18 and 90 years
- Diagnosed with sepsis or septic shock according to the diagnostic criteria in Suivival Sepsis of 2021
- Received adequate fluid resuscitation and necessary exogenous Norepinephrine (NE)
- No contraindications to Esmolol and appropriate heart rate levels determined by clinical assessment
- Provided written informed consent
Who cannot take part
- Underwent surgical procedures within the last two weeks
- Received high doses of corticosteroids in the past three months
- Underwent significant hormone therapy, persistent blood loss of more than 500 ml within any 24-hour period, or were treated with Esmolol for less than three days
- Severe cardiac failure exceeding NYHA Class III
- Deceased within three days following ICU admission
- Pregnant or lactating individuals
- Usage of long-term oral β-blockers or any form of extracorporeal circulation within the last two weeks
- Presenting with sinus bradycardia or atrioventricular block
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Evaluate the effectiveness of esmolol, a selective β1-adrenergic receptor blocker, in modulating immune responses and improving patient outcomes in sepsis.
The 2 groups in the trial
- standard care plus esmololTreatment being tested
Patients in this group were administered Esmolol, a beta-1 selective adrenergic blocker, alongside the standard sepsis care protocols. The dosage of Esmolol was adjusted to maintain heart rate within predefined targets. Additionally, daily electrocardiogram (ECG) monitoring was conducted to assess changes in the QT interval, a critical measure given the potential cardiac effects of beta-blockers. This group aimed to explore not only the immunomodulatory effects of Esmolol but also its safety profile in terms of cardiac function in septic patients.
Treatment: esmolol
- standard careNo study treatment, for comparison
Patients in this cohort received the standard of care for sepsis without any additional intervention. This treatment included antibiotics, fluids, and other supportive therapies as dictated by current clinical guidelines for sepsis management.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Investigating the Immunomodulatory Effects of Esmolol in Sepsis Management and Its Impact on Patient Outcomes
- Publications
- Esmolol improves sepsis outcomes through cardiovascular and immune modulation.Frontiers in pharmacology, 2025
- Record updated
- 29 May 2024